GlaxoSmithKline Research & Development Ltd.

Primary objective: To describe the long-term safety of multiple doses and dosing schedules of GSK1070806 in patients with moderate to severe ATD Secondary objective: To evaluate the long-term efficacy of multiple doses and dosing schedules of GSK1070806 in subjects with moderate to severe AtD

Primary: To evaluate the efficacy of Dostarlimab in subjects with previously untreated Stage II/III (locally advanced) dMMR/MSI-H colorectal cancer: cCR12 as assessed by ICR, defined as cCR maintained for 12 months. The 12-month period starts from the first disease assessment after the last dose of study drug (cCR demonstrated by ICR). Key Secondary: To further evaluate the efficacy of Dostarlimab in subjects with previously untreated Stage II/III (locally advanced) dMMR/MSI-H colorectal cancer cCR24 as assessed by ICR, defined as cCR maintained for 24 months. The 24-month period starts from the first disease assessment after the last dose of study drug (cCR demonstrated by ICR). cCR36 as assessed by ICR, defined as cCR maintained for 36 months. The 36-month period starts from the first disease assessment after the last dose of study drug (cCR demonstrated by ICR). Investigator-assessed EFS3, defined as investigator-assessed survival 3 years after the first dose of study drug in the absence of 1) inoperable disease progression, 2) local recurrence, and 3) distant recurrence.